CN108392486B - 羟基红花黄色素b在制备防治心肌缺血再灌注损伤的药物中的应用 - Google Patents
羟基红花黄色素b在制备防治心肌缺血再灌注损伤的药物中的应用 Download PDFInfo
- Publication number
- CN108392486B CN108392486B CN201810061748.0A CN201810061748A CN108392486B CN 108392486 B CN108392486 B CN 108392486B CN 201810061748 A CN201810061748 A CN 201810061748A CN 108392486 B CN108392486 B CN 108392486B
- Authority
- CN
- China
- Prior art keywords
- hydroxysafflor yellow
- myocardial
- reperfusion injury
- group
- ischemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229930195259 hydroxysafflor yellow Natural products 0.000 title claims abstract description 60
- 206010063837 Reperfusion injury Diseases 0.000 title claims abstract description 28
- 208000031225 myocardial ischemia Diseases 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title description 5
- 230000000694 effects Effects 0.000 abstract description 20
- 208000012947 ischemia reperfusion injury Diseases 0.000 abstract description 6
- 239000003963 antioxidant agent Substances 0.000 abstract description 5
- 230000003078 antioxidant effect Effects 0.000 abstract description 5
- 231100000673 dose–response relationship Toxicity 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000006909 anti-apoptosis Effects 0.000 abstract description 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 230000002107 myocardial effect Effects 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 210000001519 tissue Anatomy 0.000 description 27
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 21
- 230000010412 perfusion Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 230000006907 apoptotic process Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 208000028867 ischemia Diseases 0.000 description 11
- 108090001005 Interleukin-6 Proteins 0.000 description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
- 102100040247 Tumor necrosis factor Human genes 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 229960003180 glutathione Drugs 0.000 description 10
- 108010053070 Glutathione Disulfide Proteins 0.000 description 9
- 239000007853 buffer solution Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 8
- 208000010125 myocardial infarction Diseases 0.000 description 8
- 239000001993 wax Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 230000010410 reperfusion Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 210000005240 left ventricle Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 230000007574 infarction Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 230000036722 left ventricular developed pressure Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- -1 flavonoid compound Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 244000020518 Carthamus tinctorius Species 0.000 description 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 2
- 208000013875 Heart injury Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 230000000887 hydrating effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003680 myocardial damage Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000005077 saccule Anatomy 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- IAVUBSCVWHLRGE-UXEKTNMQSA-N (6e)-2,5-dihydroxy-6-[(e)-1-hydroxy-3-(4-hydroxyphenyl)prop-2-enylidene]-2,4-bis[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]cyclohex-4-ene-1,3-dione Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C(C(C(O)([C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C1=O)=O)=C(O)\C1=C(/O)\C=C\C1=CC=C(O)C=C1 IAVUBSCVWHLRGE-UXEKTNMQSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 206010018833 Haematocoele Diseases 0.000 description 1
- 208000005873 Hematocele Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 108091008698 baroreceptors Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- WGHKKEJHRMUKDK-UHFFFAOYSA-N cyclohexa-2,5-dien-1-one Chemical compound O=C1C=CCC=C1 WGHKKEJHRMUKDK-UHFFFAOYSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 201000004920 hematocele of tunica vaginalis testis Diseases 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- ZZMASNSDVDSYKO-UHFFFAOYSA-N hydroxysafflor yellow A Natural products OCC1OC(C(O)C(O)C1O)C2=C(O)C(O)(C3OC(CO)C(O)C(O)C3O)C(=O)C(=C2O)C(=O)C=Cc4ccc(O)cc4 ZZMASNSDVDSYKO-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000008065 myocardial cell damage Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 210000001774 pressoreceptor Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000021419 recognition of apoptotic cell Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 238000013042 tunel staining Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810061748.0A CN108392486B (zh) | 2018-01-23 | 2018-01-23 | 羟基红花黄色素b在制备防治心肌缺血再灌注损伤的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810061748.0A CN108392486B (zh) | 2018-01-23 | 2018-01-23 | 羟基红花黄色素b在制备防治心肌缺血再灌注损伤的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108392486A CN108392486A (zh) | 2018-08-14 |
CN108392486B true CN108392486B (zh) | 2020-01-03 |
Family
ID=63094153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810061748.0A Active CN108392486B (zh) | 2018-01-23 | 2018-01-23 | 羟基红花黄色素b在制备防治心肌缺血再灌注损伤的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108392486B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108743602B (zh) * | 2018-08-27 | 2021-02-26 | 滨州医学院 | 羟基红花黄色素b在制备治疗乳腺癌药物中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1765357A (zh) * | 2004-10-25 | 2006-05-03 | 山东绿叶天然药物研究开发有限公司 | 红花黄色素b在制备治疗心脑血管疾病的药物中的应用 |
CN101190906B (zh) * | 2007-06-22 | 2011-01-12 | 北京星昊医药股份有限公司 | 红花黄色素b的制备方法及其应用 |
CN103830221A (zh) * | 2012-11-21 | 2014-06-04 | 青岛百草汇中草药研究所 | 羟基红花黄色素a在制备治疗心血管疾病的药物中的应用 |
CN104230864A (zh) * | 2013-06-08 | 2014-12-24 | 浙江永宁药业股份有限公司 | 新的羟基红花黄色素a二价药用盐及其制备方法和用途 |
CN103980239B (zh) * | 2013-02-07 | 2016-04-13 | 浙江永宁药业股份有限公司 | 羟基红花黄色素a钠及其生产方法和用途 |
-
2018
- 2018-01-23 CN CN201810061748.0A patent/CN108392486B/zh active Active
Non-Patent Citations (1)
Title |
---|
Two New Quinochalcone C-Glycosides from the Florets of Carthamus tinctorius;Shijun Yue 等;《International Journal of Molecular Sciences》;20141231;第15卷;第16760-16771页 * |
Also Published As
Publication number | Publication date |
---|---|
CN108392486A (zh) | 2018-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104173365B (zh) | N6-(2-羟乙基)腺苷在抗肾衰竭中的用途 | |
CN108392486B (zh) | 羟基红花黄色素b在制备防治心肌缺血再灌注损伤的药物中的应用 | |
CN111562394B (zh) | 热休克因子2结合蛋白在肝脏缺血再灌注损伤、药物性肝损伤中的应用 | |
El-Beltagy et al. | Therapeutic role of Azadirachta indica leaves ethanolic extract against diabetic nephropathy in rats neonatally induced by streptozotocin | |
Liu et al. | Antioxidative natural product protect against econazole-induced liver injuries | |
CN109091488B (zh) | 紫云英苷治疗糖尿病性睾丸功能损伤的制药用途 | |
Zhang et al. | Liensinine pretreatment reduces inflammation, oxidative stress, apoptosis, and autophagy to alleviate sepsis acute kidney injury | |
Teoh et al. | A histological study of the structural changes in the liver of streptozotocin-induced diabetic rats treated with or without Momordica charantia (bitter gourd) | |
KR101668443B1 (ko) | 아모디아퀸을 유효성분으로 함유하는 대사성 질환의 예방, 개선, 또는 치료용 조성물 | |
CN105560265B (zh) | 柴胡多糖在制备防治糖尿病肾病的药物中的用途 | |
CN103284993A (zh) | 汉黄芩素在制备治疗慢性肾病的药物中的用途 | |
KR101938056B1 (ko) | 개꼬시래기 추출물 또는 분획물을 유효성분으로 함유하는 당뇨병의 예방 및 치료용 약학 조성물 | |
Wei et al. | Polyphenols from Sorbus aucuparia ameliorate insulin resistance and metabolic disorders in diabetic mice. | |
Ulla et al. | Supplementation of Citrus maxima fruits peel powder improves glucose intolerance and prevents oxidative stress in liver of alloxan-induced diabetic rats | |
Mulyani et al. | In vivo test of rhizophora mucronata mangrove extract from pangandaran coast towards Nile Tilapia Oreochromis niloticus infected by Vibrio harveyi | |
CN107593685B (zh) | 马尾松树皮提取物在制备移植器官保存液中的应用 | |
CN108524485A (zh) | 一种猴睾酮缺乏模型的建立方法 | |
Kintoko et al. | Hypoglycaemic activity of 2-dodecyl-6-methoxycyclohexa-2, 5-diene-1, 4-dione in streptozotocin-induced diabetic mice through ameliorating metabolic function and regulating peroxisome proliferator-activated receptor γ | |
Agbor et al. | Auricularia polytricha restores altered reproductive parameters in streptozotocin-induced diabetic Wistar rat | |
Jankyova et al. | The Evaluation of Efficacy of Pycnogenol? Fractions on Endothelial Dysfunction | |
CN115478105B (zh) | Sirt4在肝缺血疾病治疗中的应用 | |
CN115569134B (zh) | 1,4-[二(1,2-苯并异硒唑-3(2h)-酮)]丁烷及其组合物的医药用途 | |
CN104352593B (zh) | 一种治疗糖尿病的药物组合物 | |
NAJI et al. | Treatment of burns associated with diabetes with tannins extracted from Haloxylon salicornium and Zygophilium coccinium | |
CN117462547B (zh) | Nsc668394在制备铁死亡抑制剂及预防缺血再灌注损伤药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of hydroxysafflower yellow B in the preparation of drugs for the prevention and treatment of myocardial ischemia-reperfusion injury Effective date of registration: 20211214 Granted publication date: 20200103 Pledgee: Yantai financing guarantee Group Co.,Ltd. Pledgor: BINZHOU MEDICAL University Registration number: Y2021980014859 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20200103 Pledgee: Yantai financing guarantee Group Co.,Ltd. Pledgor: BINZHOU MEDICAL University Registration number: Y2021980014859 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |